Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis

Explore clinical trials studying Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

2,361 public trials 354 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis trial results

Completed

TMP001 in Relapsing-remitting Multiple Sclerosis

NCT02686788

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • UKT, Universitätsklinikum Tübingen Tübingen, Baden-Würtemberg, Germany
  • Goethe-Universität Frankfurt am Main Frankfurt am Main, Hesse, Germany
  • Universitätsklinikum Münster, Klinik für Allgemeine Neurologie Münster, North Rhine-Westphalia, Germany
  • Charite- Universitätsmedizin Berlin (Campus Mitte) NeuroCure Clinical Research Center NCRC AG Klinische Neuroimmunologie Berlin, Germany
View Trial Details
Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01838668

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Fakultni nemocnice u sv. Anny v Brne Brno, Czechia
  • Neurospol, s.r.o. Havířov, Czechia
  • Fakultni nemocnice Hradec Kralove Hradec Králové, Czechia
  • Privatni ordinace - neurologie Hradec Králové, Czechia
View all 54 locations
View Trial Details
Completed

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +11 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Phoenix, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tucson, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fullerton, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States
View all 63 locations
View Trial Details
Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

NCT01051349

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Brno, Czechia
  • Research Site Hradec Králové, Czechia
  • Research Site Prague, Czechia
View all 65 locations
View Trial Details
Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766

Conditions
Actinomycetales Infections, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +12 more
Locations
  • Research Site Scottsdale, Arizona, United States
  • Research Site Long Beach, California, United States
  • Research Site Sacramento, California, United States
  • Research Site Denver, Colorado, United States
View all 16 locations
View Trial Details

Related conditions